tiprankstipranks
Trending News
More News >
Enhabit, Inc (EHAB)
NYSE:EHAB
US Market

Enhabit, Inc (EHAB) AI Stock Analysis

Compare
31 Followers

Top Page

EH

Enhabit, Inc

(NYSE:EHAB)

Rating:52Neutral
Price Target:
$9.50
▼(-0.11%Downside)
Enhabit, Inc. receives a score of 52, mainly due to operational challenges and negative valuation metrics. Financial performance is under pressure from declining revenues and negative profitability, though stable cash flows and balance sheet provide some support. Positive signals from recent earnings call regarding growth and cost efficiency improvements contribute positively but are outweighed by technical and valuation concerns.
Positive Factors
Earnings
EPS of $0.10 came in above consensus.
Financial Performance
The stock is seen positively due to its relatively low valuation and potential for EBITDA upside driven by continued improvements in key performance indicators.
Payer Innovation Strategy
The company is advancing its payer innovation strategy, with a notable increase in non-Medicare revenue per visit.
Negative Factors
Home Health Performance
Home Health faced a challenging rate and mix environment, resulting in performance falling short of forecasts.
Revenue Shortfall
Home Health revenues of $200.6m fell short of the estimate by about 7%.
Segment Outlook
The Home Health segment revenue outlook is slightly lowered with continued margin pressure expected.

Enhabit, Inc (EHAB) vs. SPDR S&P 500 ETF (SPY)

Enhabit, Inc Business Overview & Revenue Model

Company DescriptionEnhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
How the Company Makes MoneyEnhabit, Inc generates revenue primarily through the reimbursement of its healthcare services. The company's key revenue streams include payments from Medicare, Medicaid, private insurance companies, and direct payments from patients. Enhabit's earnings are significantly influenced by its ability to maintain relationships with healthcare providers, government programs, and insurance companies, ensuring a steady influx of patients requiring home health and hospice care. The company's financial performance is also affected by regulatory changes and reimbursement rate adjustments that impact the healthcare industry.

Enhabit, Inc Earnings Call Summary

Earnings Call Date:May 07, 2025
(Q1-2025)
|
% Change Since: 15.98%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant growth in admissions and revenue in both the home health and hospice segments. There were also notable improvements in cost efficiency and financial performance. However, there were challenges such as a decline in total home health census and a year-over-year decrease in consolidated revenue. Branch closures were also a concern. Overall, the positive aspects of growth and financial improvements slightly outweigh the negative aspects.
Q1-2025 Updates
Positive Updates
Home Health Admissions Growth
Admissions increased by 8.1% from Q4 to Q1, with fee-for-service growing 4% sequentially. Year-over-year admission growth was up 0.7% and normalized growth was 2.5%.
Growth in Non-Medicare Revenue
Non-Medicare admissions increased by 7.4% year-over-year, driven by payer innovation contracts. Non-Medicare revenue per visit improved by 7.6% year-over-year.
Hospice Segment Performance
Total admissions grew 8% year-over-year with 5.2% same-store growth. Census grew by 12.3% with 10.6% same-store growth.
Cost Efficiency Improvements
Cost per day decreased by 0.8% year-over-year and 2.7% sequentially in the hospice segment. Completed transition to outsourced coding resource expected to save $1.5 million for 2025.
Financial Performance
Home health segment EBITDA improved by 7.9% sequentially. Hospice segment EBITDA grew by 65% year-over-year. Q1 2025 leverage ratio improved to 4.4x.
Balance Sheet and Cash Flow
Generated approximately $17 million of free cash flow and reduced overall bank debt by $25 million in the quarter.
Negative Updates
Decline in Total Home Health Census
Total home health census was down 2.4% year-over-year due to a low entry point in January.
Decreased Revenue Year-over-Year
Consolidated net revenue decreased by $2.5 million or 1.0% year-over-year.
Branch Closures
Seven branches were closed or consolidated in the first quarter, with four more expected to close by the end of Q2 2025.
Company Guidance
During Enhabit Home Health & Hospice's first quarter 2025 earnings call, several key performance metrics and strategic initiatives were highlighted. The company reported an 8.1% increase in admissions from Q4 2024 to Q1 2025, with fee-for-service admissions growing by 4% sequentially. Year-over-year admission growth normalized for Leap Year and branch closures was up 2.5%. Total home health census increased by 3.7% sequentially, despite a 2.4% year-over-year decline due to a low entry point in January. Non-Medicare admissions rose by 7.4% year-over-year, driven by payer innovation contracts, which accounted for 44% of non-Medicare visits in Q1 2025, up from 38% in Q1 2024. This shift contributed to a 7.6% increase in non-Medicare revenue per visit. Visits per episode decreased by 6.7% to 13.9%. In the hospice segment, admissions grew by 8% year-over-year, and the average daily census increased by 12.3%. The company also reported a 310 basis point improvement in referral-to-admission conversion year-over-year. Additionally, Enhabit completed the transition to outsourced coding resources, estimated to save $1.5 million in 2025, and closed or consolidated seven branches, with four more closures planned by the end of Q2 2025. The company reaffirmed its 2025 guidance based on strong Q1 results and business momentum.

Enhabit, Inc Financial Statement Overview

Summary
Enhabit, Inc. faces significant challenges with declining revenue and persistent net losses impacting profitability and returns. However, the balance sheet remains stable with manageable leverage, and cash flows are positive, providing some resilience.
Income Statement
45
Neutral
The company has been experiencing declining revenues, with a TTM revenue of $1.032 billion compared to $1.048 billion in the previous year. Gross profit margin is relatively strong at 46.7% TTM, but net profit margin is negative due to significant net losses. The EBIT and EBITDA margins are also negative, indicating operational challenges. Overall, the income statement reflects financial pressures and declining profitability.
Balance Sheet
55
Neutral
The balance sheet shows a moderate equity position with a debt-to-equity ratio of 0.18 TTM, reflecting manageable leverage. However, the return on equity is negative due to net losses. The equity ratio is reasonable at 44% TTM, indicating a stable capital structure. Despite these strengths, persistent losses pose a risk to financial stability.
Cash Flow
60
Neutral
The company's cash flow position is relatively stable, with positive operating cash flow of $51.8 million TTM and positive free cash flow of $49.5 million. The free cash flow to net income ratio is not meaningful due to negative net income, but the operating cash flow to net income ratio is robust, indicating effective cash generation despite losses. Cash reserves are modest but consistent.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.03B1.03B1.05B1.08B1.11B1.08B
Gross Profit481.80M504.00M510.70M557.50M592.70M540.70M
EBITDA-62.80M-83.60M-16.50M22.50M185.20M145.40M
Net Income-138.60M-156.20M-80.50M-40.40M111.10M75.00M
Balance Sheet
Total Assets1.24B1.23B1.43B1.65B1.72B1.62B
Cash, Cash Equivalents and Short-Term Investments39.50M28.40M27.40M22.90M5.40M38.50M
Total Debt100.00K569.50M610.10M625.20M56.90M50.50M
Total Liabilities662.60M672.10M731.90M767.30M236.70M227.00M
Stockholders Equity543.20M523.50M669.70M844.60M1.47B1.38B
Cash Flow
Free Cash Flow49.50M47.40M44.90M73.00M117.70M21.30M
Operating Cash Flow51.80M51.20M48.40M80.10M123.30M24.90M
Investing Cash Flow19.50M-2.40M-5.30M-42.30M-119.20M-3.00M
Financing Cash Flow-69.90M-48.30M-40.50M-18.60M-36.10M-16.70M

Enhabit, Inc Technical Analysis

Technical Analysis Sentiment
Positive
Last Price9.51
Price Trends
50DMA
9.47
Positive
100DMA
8.97
Positive
200DMA
8.36
Positive
Market Momentum
MACD
-0.12
Positive
RSI
44.51
Neutral
STOCH
43.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EHAB, the sentiment is Positive. The current price of 9.51 is below the 20-day moving average (MA) of 10.02, above the 50-day MA of 9.47, and above the 200-day MA of 8.36, indicating a neutral trend. The MACD of -0.12 indicates Positive momentum. The RSI at 44.51 is Neutral, neither overbought nor oversold. The STOCH value of 43.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EHAB.

Enhabit, Inc Risk Analysis

Enhabit, Inc disclosed 27 risk factors in its most recent earnings report. Enhabit, Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Enhabit, Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$8.82B28.8117.66%0.16%16.80%39.99%
HCHCA
76
Outperform
$91.25B16.85-230.22%0.76%7.30%11.60%
71
Outperform
$3.22B36.287.85%5.34%
69
Neutral
$1.03B38.8811.28%30.04%43.47%
53
Neutral
$515.75M-12.03%12.19%-1.59%
52
Neutral
$475.99M-22.81%-1.08%-65.84%
51
Neutral
$7.41B0.36-61.88%2.34%16.99%1.69%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
EHAB
Enhabit, Inc
9.56
0.81
9.26%
AMED
Amedisys
97.92
1.24
1.28%
HCA
HCA Healthcare
379.30
66.69
21.33%
ENSG
The Ensign Group
153.35
29.38
23.70%
PNTG
Pennant Group
29.80
6.40
27.35%
INNV
InnovAge Holding
3.92
-1.12
-22.22%

Enhabit, Inc Corporate Events

Executive/Board ChangesShareholder Meetings
Enhabit, Inc Approves 2025 Equity Compensation Plan
Neutral
Jun 26, 2025

On June 26, 2025, Enhabit, Inc. held its Annual Meeting of Stockholders, where the 2025 Equity and Incentive Compensation Plan was approved. This plan, administered by the Compensation & Human Capital Committee, allows for various equity and cash-based awards to company officers, employees, and non-employee directors, with a total of 3,300,000 shares available for awards under specific conditions. Additionally, the meeting included the election of directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and an advisory vote on executive compensation.

The most recent analyst rating on (EHAB) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Enhabit, Inc stock, see the EHAB Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Enhabit, Inc to Present at Global Healthcare Conference
Positive
Jun 9, 2025

Enhabit, Inc. announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, where its executives will discuss the company’s strategic priorities and financial performance. The company has shown significant growth in its home health and hospice segments, with improvements in patient census and financial metrics, indicating a positive trajectory and reduced leverage, which may enhance its market position and stakeholder confidence.

The most recent analyst rating on (EHAB) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Enhabit, Inc stock, see the EHAB Stock Forecast page.

Financial Disclosures
Enhabit, Inc Reports Q1 2025 Financial Results
Positive
May 7, 2025

Enhabit, Inc. reported its first quarter 2025 financial results, highlighting a 3.7% sequential growth in home health census and a 12.3% year-over-year increase in hospice census. The company achieved a net income of $17.8 million and an adjusted EBITDA of $26.6 million, benefiting from improved profitability and a reduced leverage ratio, which allows for more favorable debt pricing and operational flexibility.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 24, 2025